An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
Phase of Trial: Phase IV
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Interferon alpha
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Merck & Co
- 12 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 12 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 09 Nov 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.